BR112023014549A2 - Compostos derivados substituídos com ip4-4,6 - Google Patents
Compostos derivados substituídos com ip4-4,6Info
- Publication number
- BR112023014549A2 BR112023014549A2 BR112023014549A BR112023014549A BR112023014549A2 BR 112023014549 A2 BR112023014549 A2 BR 112023014549A2 BR 112023014549 A BR112023014549 A BR 112023014549A BR 112023014549 A BR112023014549 A BR 112023014549A BR 112023014549 A2 BR112023014549 A2 BR 112023014549A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- derivative compounds
- methods
- compounds replaced
- derivative
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
compostos derivados substituídos com ip4-4,6. provê derivados substituídos com ip4-4,6, seus métodos de síntese e seus usos. em alguns aspectos, o derivado de ip4-4,6 é um composto de fórmula i em que r1, r3, r7, e r11 são opo32-, e r5 e r9 são selecionados do grupo que consiste em -o(alquil)nx, -o(alquil)ycy(alquil2)y-z, -o(alquil)ya(alquil)y-z', e seus análogos de tiofosfato. são também são providos métodos, composições farmacêuticas e formulações, métodos de uso, artigos de fabricação, e kits para o tratamento de doenças e condições tais como doenças e condições relacionadas a cristalização patológica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21382075.6A EP4036097A1 (en) | 2021-01-29 | 2021-01-29 | Ip4-4,6 substituted derivative compounds |
PCT/EP2022/052164 WO2022162206A1 (en) | 2021-01-29 | 2022-01-31 | Ip4-4,6 substituted derivative compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023014549A2 true BR112023014549A2 (pt) | 2023-10-10 |
Family
ID=74732816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023014549A BR112023014549A2 (pt) | 2021-01-29 | 2022-01-31 | Compostos derivados substituídos com ip4-4,6 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240109924A1 (pt) |
EP (2) | EP4036097A1 (pt) |
JP (1) | JP2024504257A (pt) |
KR (1) | KR20230132811A (pt) |
CN (1) | CN116745304A (pt) |
AR (1) | AR124717A1 (pt) |
AU (1) | AU2022212601A1 (pt) |
BR (1) | BR112023014549A2 (pt) |
CA (1) | CA3202780A1 (pt) |
IL (1) | IL303825A (pt) |
MX (1) | MX2023008250A (pt) |
TW (1) | TW202239414A (pt) |
WO (1) | WO2022162206A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024023359A1 (en) * | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755612A (en) * | 1987-07-20 | 1988-07-05 | Merck & Co., Inc. | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5264605A (en) * | 1989-06-28 | 1993-11-23 | Mitsui Toatsu Chemicals, Incorporated | Myoinsitol derivatives, process for preparing same, phosphorylating agent, and its utilization |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
EP0632720B1 (en) | 1992-03-25 | 1998-11-11 | Depomed Systems, Inc. | Hydroxyethylcellulose-based sustained-release oral drug dosage froms |
AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
JP4083818B2 (ja) | 1997-06-06 | 2008-04-30 | ディポメド,インコーポレイティド | 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形 |
NZ518739A (en) | 1999-11-02 | 2004-12-24 | Depomed Inc | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
ATE340563T1 (de) | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
WO2002096404A1 (en) | 2001-05-29 | 2002-12-05 | Depomed Development Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
JP6893037B2 (ja) | 2015-12-11 | 2021-06-23 | エーテーハー・チューリッヒETH Zurich | C.difficile感染のための4,6−ジ−(O−チオホスフェート)−イノシトール−1,2,3,5−テトラ−O−スルフェート |
ES2870521T3 (es) | 2015-12-11 | 2021-10-27 | Eth Zuerich | Derivados de inositol para su uso en la cristalización patológica |
-
2021
- 2021-01-29 EP EP21382075.6A patent/EP4036097A1/en not_active Withdrawn
-
2022
- 2022-01-27 TW TW111103698A patent/TW202239414A/zh unknown
- 2022-01-28 AR ARP220100172A patent/AR124717A1/es unknown
- 2022-01-31 US US18/274,805 patent/US20240109924A1/en active Pending
- 2022-01-31 AU AU2022212601A patent/AU2022212601A1/en active Pending
- 2022-01-31 JP JP2023537515A patent/JP2024504257A/ja active Pending
- 2022-01-31 EP EP22703600.1A patent/EP4284809A1/en active Pending
- 2022-01-31 CN CN202280012575.8A patent/CN116745304A/zh active Pending
- 2022-01-31 KR KR1020237027325A patent/KR20230132811A/ko unknown
- 2022-01-31 MX MX2023008250A patent/MX2023008250A/es unknown
- 2022-01-31 CA CA3202780A patent/CA3202780A1/en active Pending
- 2022-01-31 BR BR112023014549A patent/BR112023014549A2/pt unknown
- 2022-01-31 WO PCT/EP2022/052164 patent/WO2022162206A1/en active Application Filing
- 2022-01-31 IL IL303825A patent/IL303825A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4036097A1 (en) | 2022-08-03 |
TW202239414A (zh) | 2022-10-16 |
CA3202780A1 (en) | 2022-08-04 |
JP2024504257A (ja) | 2024-01-31 |
IL303825A (en) | 2023-08-01 |
CN116745304A (zh) | 2023-09-12 |
AR124717A1 (es) | 2023-04-26 |
KR20230132811A (ko) | 2023-09-18 |
AU2022212601A1 (en) | 2023-07-06 |
US20240109924A1 (en) | 2024-04-04 |
EP4284809A1 (en) | 2023-12-06 |
MX2023008250A (es) | 2023-07-26 |
WO2022162206A1 (en) | 2022-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR072233A1 (es) | Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
BR112015012454A8 (pt) | compostos inibidores de atr quinase, seu uso, composição farmacêutica compreendendo os mesmos, seus intermediários e método de preparação | |
ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
UY32025A (es) | Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones. | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
ECSP088773A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
AR071548A1 (es) | Amidas de acido 3-substituido-4-oxo-3, 4-dihidro-imidazo[5, 1-d]1, 2, 3, 5-tetracina-8-carboxilico, un metodo para su preparacion e intermediarios de su sintesis, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de diversos tipos de cancer | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
CR11208A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
AR052413A1 (es) | Nuevos derivados de piridotienopiriidina | |
UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
BR112023014549A2 (pt) | Compostos derivados substituídos com ip4-4,6 | |
CU20230009A7 (es) | Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irak | |
UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
NO20055167L (no) | Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem |